OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
April 02, 2021
After Brexit there is an increased risk of the UK being exposed to counterfeit medicines, but regulations implementing blockchain as infrastructure technology could be the answer.
January 03, 2021
Despite the COVID-19 pandemic disruptions, with continued support and industry resilience, the European bio/pharma outlook for 2021 is positive.
November 03, 2020
Bio/pharma continues preparations for a no-deal scenario as time for the UK and EU to agree upon a new deal runs out.
November 02, 2020
Industry wants clarification on compliance following the end of the Brexit transition period.
July 02, 2020
EMA is facing a dilemma in trying to restore activities back to normal after relocating and the COVID-19 pandemic.
As Brexit talks intensify, bio/pharma companies from both the UK and EU need to consider and aim to prepare for all scenarios.
June 05, 2020
The protocol on Northern Ireland (NI) once Brexit has been completed has received mixed opinions in industry, according to various press releases.
February 27, 2020
ABPI has issued a statement noting that it shares the ambition of the United Kingdom’s government, as set out in its published approach to the negotiations for the future relationship with the European Union (EU).
February 13, 2020
According to executive search firm Odgers Berndtson, its recent poll has highlighted that senior executives in life sciences believe there is a positive future for the United Kingdom’s sector outside the European Union.
February 02, 2020
The UK and Europe are entering a transitional period, which will involve negotiations across the board, including those on the pharma regulatory landscape.